Intrarosa Compounding Legal Status: What Women Need to Know About Prasterone Vaginal DHEA

What Is Intrarosa and Why Does Its Regulatory Status Matter to You?

Intrarosa is the only FDA-approved vaginal insert containing prasterone, a synthetic form of dehydroepiandrosterone (DHEA). When inserted vaginally, prasterone is converted locally into estrogens and androgens inside vaginal cells, without significantly raising blood hormone levels. That local conversion is the reason clinicians prescribe it for genitourinary syndrome of menopause (GSM), a condition affecting up to 50% of postmenopausal women.

The regulatory status matters to you for one practical reason: FDA approval of a drug changes what compounding pharmacies can legally prepare. Many women pay out-of-pocket for hormone therapy and assume a compounding pharmacy can always make a cheaper version. For Intrarosa, that assumption is wrong in most circumstances.

What Is GSM and Who Gets It?

GSM describes the cluster of symptoms that arise when estrogen and androgen levels drop after menopause: vaginal dryness, itching, burning, painful sex (dyspareunia), and urinary urgency. Unlike hot flashes, GSM does not improve with time. It tends to worsen without treatment.

About 15% of women report moderate-to-severe dyspareunia during the postmenopausal years, making it one of the most common and underreported conditions in women over 50.

Perimenopause and Prasterone

Perimenopausal women can experience GSM symptoms years before their final menstrual period, particularly those with surgically induced menopause or those using GnRH agonists for endometriosis or fibroids. Intrarosa's FDA approval is limited to postmenopausal women. Use in perimenopause is off-label, and no dedicated perimenopausal trial data exists. Clinicians who prescribe it perimenopausal women are extrapolating from the postmenopausal dataset.

The FDA Approval: What the Label Actually Says

The FDA approved Intrarosa on November 16, 2016, under NDA 208470, making it the first non-estrogen prescription treatment approved specifically for GSM-related dyspareunia. The approved dose is one 6.5 mg vaginal insert placed nightly using a disposable applicator.

What the Label Covers

The prescribing information specifies the indication precisely: moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. The label does not cover:

• Urinary symptoms of GSM (urgency, recurrent UTIs) as a standalone indication
• Libido or sexual desire disorders (though androgen conversion may have effects)
• Use in premenopausal or perimenopausal women
• Use in women with breast cancer or any estrogen/androgen-sensitive malignancy

The FDA prescribing information carries a specific warning that prasterone has not been adequately studied in women with a history of breast cancer. Given that prasterone converts to both estradiol and testosterone locally, clinicians are advised to use caution in any woman with a personal or strong family history of hormone-sensitive cancer.

The Boxed Warning Situation

Intrarosa does not carry a Black Box warning, which distinguishes it from systemic estrogen and systemic estrogen-progestogen products. The FDA label notes that systemic absorption of prasterone-derived estrogens and androgens is measurable but low, and the clinical significance of that systemic exposure over long durations has not been fully characterized. This is a real evidence gap, discussed further below.

The Key Clinical Trial: What the Evidence Shows

The cornerstone trial supporting FDA approval was a phase 3 randomized, double-blind, placebo-controlled study published in the journal Menopause in 2016 (PMID 27749790). The trial enrolled 416 postmenopausal women with moderate-to-severe dyspareunia and randomized them to 6.5 mg prasterone vaginal insert nightly or placebo for 12 weeks.

Key Outcomes from the Phase 3 Trial

The prasterone group showed statistically significant improvements across all four co-primary endpoints required by the FDA:

• Vaginal dryness severity decreased significantly versus placebo (p < 0.001)
• Dyspareunia severity improved by approximately 1.5 points on a 4-point scale compared with 0.9 points for placebo
• Percentage of parabasal cells (a marker of vaginal atrophy) decreased substantially
• Vaginal pH dropped toward premenopausal range (below 5.0) in the prasterone group

Serum DHEA, testosterone, and estradiol levels rose slightly above baseline in the prasterone group but remained within the normal postmenopausal reference range. This is clinically meaningful: the local conversion does not appear to drive systemic hormone levels outside accepted parameters at the approved dose.

What the Trial Did Not Measure

The 12-week trial was not powered to detect long-term safety outcomes such as cardiovascular events, venous thromboembolism, or breast cancer incidence. Women with prior breast cancer were excluded. This is the most significant evidence gap in the Intrarosa dataset, and it is one your clinician should discuss with you before prescribing.

WomanRx Life-Stage Evidence Framework for Prasterone Vaginal:

| Life Stage | Evidence Base | Clinical Status | |---|---|---| | Postmenopause (natural) | Phase 3 RCT, 12 weeks, n=416 | FDA-approved, on-label | | Surgical menopause | Subgroup data only | On-label (meets postmenopausal criterion) | | Perimenopause | None | Off-label; extrapolated | | Trying to conceive | None; contraindicated | Do not use | | Pregnancy | None; contraindicated | Do not use | | Breast cancer survivors | Excluded from all trials | No approved guidance; use with caution or avoid |

Compounding Legal Status: Can Your Pharmacy Make It?

This is the question most women searching "Intrarosa compounding legal status" actually want answered. The answer is: in most cases, no.

The Federal Framework for Compounding

Under the Drug Quality and Security Act (DQSA) of 2013, FDA-approved drugs cannot be freely copied by compounding pharmacies. Two sections govern this:

Section 503A covers traditional compounding pharmacies. They may compound a copy of an FDA-approved drug only if:

1. A licensed prescriber provides a patient-specific prescription
2. The drug is not "essentially a copy" of the commercially available product
3. The drug appears on the FDA's list of bulk substances that may be compounded, OR a valid clinical difference exists (different strength, dosage form, or excipient that serves a documented medical need)

Section 503B covers outsourcing facilities. These facilities may compound from bulk APIs only if the drug is on the FDA's 503B bulks list.

Where Prasterone Stands on the FDA Lists

Prasterone (DHEA) as a bulk API has been nominated for the 503B bulks list, but FDA has not placed it on the Category 1 (approved for use) list. Without Category 1 status, 503B outsourcing facilities cannot legally compound bulk prasterone for distribution.

For 503A pharmacies compounding patient-specific prescriptions, the "essentially a copy" restriction is the central problem. A 6.5 mg prasterone vaginal insert that replicates Intrarosa's formulation is, by definition, essentially a copy of an approved product. A compounding pharmacy can argue a clinical difference only if:

• The patient requires a strength not commercially available (e.g., 3.25 mg for tolerability)
• The patient has a documented allergy to an excipient in the commercial product
• The prescriber documents a specific clinical rationale in writing

Without one of those justifications, FDA considers the compounded version an unapproved new drug, subject to enforcement action.

Why This Matters Practically

Many compounding pharmacies have marketed vaginal DHEA suppositories for years, often at lower cost than branded Intrarosa. Before November 2016, that was legally straightforward because no approved product existed. After FDA approval of Intrarosa, the regulatory field changed. Women who received compounded vaginal DHEA before 2016 were in a legally and clinically different situation than women who receive it today.

If your compounding pharmacy is currently filling a vaginal DHEA prescription without documented clinical justification, they may be operating outside FDA guidance. This does not automatically mean the product is unsafe, but it does mean:

• Quality, sterility, and dose accuracy are not FDA-verified
• Your insurer will not cover it (coverage decisions for the compounded version differ from the branded product)
• Your pharmacist carries regulatory risk

Pregnancy, Lactation, and Contraception: What You Must Know

Prasterone vaginal inserts are contraindicated during pregnancy.

Pregnancy

DHEA is an androgen precursor. Systemic androgen exposure during pregnancy, even from vaginal absorption, carries a theoretical risk of virilizing a female fetus. There are no adequate, well-controlled studies of prasterone in pregnant women. The FDA label explicitly states Intrarosa should not be used during pregnancy.

Because the approved indication is postmenopausal dyspareunia, pregnancy during Intrarosa use is unlikely but not impossible in perimenopausal women who still have residual ovarian function. Any perimenopausal woman prescribed prasterone off-label who has not reached confirmed menopause (12 consecutive months without a period) should use reliable contraception.

Lactation

No human lactation data exists for vaginal prasterone. Given that measurable systemic absorption occurs, and DHEA metabolites include estradiol and testosterone, caution is warranted. Androgens in breast milk may affect a nursing infant. The FDA label does not address lactation explicitly, which itself reflects a data gap. Women who are breastfeeding should not use Intrarosa until more data are available.

Contraception Requirement

Premenopausal and perimenopausal women using vaginal prasterone off-label should use a non-hormonal barrier method or copper IUD. Combined hormonal contraceptives may interact with the androgen/estrogen milieu created by prasterone conversion, though no formal drug interaction studies have been conducted. This is an extrapolation, not a studied recommendation.

Safety Profile: What to Expect and What to Watch For

Intrarosa's safety profile, based on the phase 3 trial data and the FDA prescribing information, is generally favorable for short-term use.

Common Side Effects

• Vaginal discharge: The most frequently reported adverse event, occurring in approximately 10% of users in the trial. This is usually white or off-white and related to the insert vehicle melting.
• Abnormal Pap smear: Reported at a slightly higher rate in the prasterone group. The clinical significance is unclear; most were low-grade findings that resolved.
• Vulvovaginal discomfort: Reported in a small percentage and typically mild.

No serious cardiovascular events, thromboembolic events, or breast cancers were attributed to prasterone in the 12-week trial. The trial was not powered or long enough to detect these outcomes.

Hormone-Sensitive Conditions

Because prasterone converts to estrogens and androgens locally, women with the following conditions require careful risk-benefit discussion before use:

• Hormone receptor-positive breast cancer (past or current): Excluded from trials; no safety data
• Endometriosis: Estrogen conversion could theoretically stimulate endometrial implants
• Uterine fibroids: Estrogen and androgen conversion may affect fibroid growth
• PCOS: Women with PCOS already have elevated androgen levels; additional androgen substrate from DHEA conversion is not well-studied

The Menopause Society (formerly NAMS) 2023 position statement on GSM supports vaginal prasterone as an effective, non-estrogen option for postmenopausal women with dyspareunia, while acknowledging the absence of long-term cardiovascular and cancer safety data.

The Systemic Absorption Question

One reason Intrarosa is attractive to women who want to avoid systemic hormones is the claim that it acts locally. The trial data supports low systemic absorption at the 6.5 mg dose. Serum estradiol levels remained below 10 pg/mL in most participants, within postmenopausal reference ranges. Testosterone rose modestly but remained within the normal female reference range.

Women who are specifically avoiding any systemic hormone exposure (for example, breast cancer survivors on aromatase inhibitors) should discuss this absorption data with their oncologist before starting Intrarosa, because even low systemic estradiol may be clinically relevant in that context.

Who Is This Right For and Who Should Avoid It?

Intrarosa is best suited for specific clinical profiles. Getting this decision right depends heavily on your life stage and medical history.

Right For

• Postmenopausal women with confirmed moderate-to-severe dyspareunia who want a non-systemic option
• Women who cannot or prefer not to use vaginal estrogen (though vaginal estrogen remains highly effective and is the ACOG-recommended first-line option for GSM)
• Women concerned about systemic estrogen exposure who have been counseled about Intrarosa's actual absorption profile
• Women with vaginal dryness and dyspareunia who have not responded to over-the-counter lubricants or moisturizers

Not Right For

• Pregnant women (contraindicated)
• Breastfeeding women (insufficient data; avoid)
• Women with hormone receptor-positive breast cancer unless cleared by their oncologist
• Women with undiagnosed abnormal uterine bleeding (investigation must precede hormone therapy of any kind)
• Premenopausal women seeking treatment for vaginal dryness who have not been assessed for other causes (infections, low estrogen from hypothalamic amenorrhea, medication side effects)

PCOS and Prasterone: A Specific Caution

Women with PCOS already carry elevated androgen levels in their reproductive years. By the time they reach postmenopause, their androgen milieu differs from women without PCOS. Adding an androgen precursor via vaginal prasterone has not been studied in postmenopausal women with prior PCOS. Clinicians should monitor free testosterone and DHEAS levels if prescribing in this population.

How Intrarosa Compares to Other GSM Treatments

Understanding where prasterone sits among your options helps you and your clinician make a better decision.

| Treatment | FDA-Approved | Systemic Absorption | Compounding Status | |---|---|---|---| | Vaginal estradiol cream (Estrace) | Yes | Low | Restricted (approved product exists) | | Vaginal estradiol ring (Estring) | Yes | Very low | Not compoundable | | Vaginal estradiol tablet (Vagifem/Yuvafem) | Yes | Very low | Restricted | | Prasterone insert (Intrarosa) | Yes | Low (metabolites) | Restricted (approved product exists) | | Ospemifene (Osphena) oral | Yes | Systemic (oral SERM) | Not applicable | | Compounded vaginal DHEA | No | Variable | Legally restricted post-2016 | | Vaginal moisturizers (OTC) | OTC; not FDA drug approval | None | N/A |

ACOG's 2022 clinical practice guideline on GSM supports all of the above prescription options as effective, with the choice depending on patient preference, history, and access.

The Evidence Gap: What We Do Not Know Yet

Women deserve honesty about what the data does and does not cover.

The 12-week trial duration means there is no long-term safety data specific to Intrarosa. Women frequently use GSM treatments for years or decades. The FDA label acknowledges that endometrial safety has not been assessed beyond 12 weeks and that the effects of prasterone on breast tissue over time are unknown.

This evidence gap is not unique to Intrarosa. As The Menopause Society has noted, women have been historically underrepresented in long-term hormone safety trials, and most available data comes from trials designed primarily around cardiovascular or osteoporosis endpoints, not GSM-specific outcomes.

What is extrapolated versus directly studied:

• Directly studied: Vaginal cytology improvement, pH normalization, dyspareunia severity, 12-week serum hormone levels
• Extrapolated: Long-term cardiovascular safety, breast cancer risk, endometrial safety beyond 12 weeks, safety in women with active hormone-sensitive conditions